- Home
- AIMD vs GOVX Comparison
AIMD vs GOVX Comparison
Compare AIMD & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIMD
- GOVX
- Stock Information
- Founded
- AIMD 1984
- GOVX 2001
- Country
- AIMD United States
- GOVX United States
- Employees
- AIMD N/A
- GOVX N/A
- Industry
- AIMD Biotechnology: Pharmaceutical Preparations
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- AIMD Health Care
- GOVX Health Care
- Exchange
- AIMD Nasdaq
- GOVX Nasdaq
- Market Cap
- AIMD 16.9M
- GOVX 17.4M
- IPO Year
- AIMD N/A
- GOVX N/A
- Fundamental
- Price
- AIMD $3.43
- GOVX $0.68
- Analyst Decision
- AIMD
- GOVX Strong Buy
- Analyst Count
- AIMD 0
- GOVX 3
- Target Price
- AIMD N/A
- GOVX $10.67
- AVG Volume (30 Days)
- AIMD 88.9K
- GOVX 591.0K
- Earning Date
- AIMD 11-05-2025
- GOVX 11-11-2025
- Dividend Yield
- AIMD N/A
- GOVX N/A
- EPS Growth
- AIMD N/A
- GOVX N/A
- EPS
- AIMD N/A
- GOVX N/A
- Revenue
- AIMD $110,870.00
- GOVX $6,143,044.00
- Revenue This Year
- AIMD N/A
- GOVX N/A
- Revenue Next Year
- AIMD N/A
- GOVX N/A
- P/E Ratio
- AIMD N/A
- GOVX N/A
- Revenue Growth
- AIMD 70.25
- GOVX 1943.07
- 52 Week Low
- AIMD $2.00
- GOVX $0.43
- 52 Week High
- AIMD $5.00
- GOVX $3.88
- Technical
- Relative Strength Index (RSI)
- AIMD 49.24
- GOVX 41.05
- Support Level
- AIMD $3.30
- GOVX $0.67
- Resistance Level
- AIMD $3.61
- GOVX $0.73
- Average True Range (ATR)
- AIMD 0.26
- GOVX 0.04
- MACD
- AIMD -0.06
- GOVX -0.00
- Stochastic Oscillator
- AIMD 18.29
- GOVX 24.14
About AIMD Ainos Inc.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.